加巴喷丁治疗偏头痛的有效性和安全性——随机、双盲对照研究  

Efficacy and safety of gabapentin in the treatment of migraine:a double-blind randomized placebo-controlled study

作　　者：葛林通[1] 林力[1] 吴慧娟[1] 张菁[1] 

机构地区：[1]武汉大学医学院附属中山医院神经内科

出　　处：《中国临床药理学与治疗学》2008年第4期445-448,共4页Chinese Journal of Clinical Pharmacology and Therapeutics

摘　　要：目的:评价加巴喷丁治疗偏头痛的有效性及安全性。方法:采用随机、双盲、安慰剂平行对照研究,为期8周,共有104例偏头痛患者(年龄18～60岁)被随机分至治疗组和对照组。治疗组:55例,接受加巴喷丁治疗4周;对照组:49例,口服安慰剂4周。在开始治疗时及治疗后4周、8周时采用数字评价量表对患者的疼痛程度进行评估,同时监测患者的肝肾功能、经颅多普勒超声(TCD)、脑电图(EEG)及药物不良反应。结果:4周后加巴喷丁治疗组患者头痛发生率(次/月)、持续时间(h)、疼痛程度(分)均明显下降,分别由6.4±2.5降至2.3±1.5、21.8±12.6下降至8.6±4.3、8.6±1.2降至2.4±1.1。与对照组比较,差异有统计学意义(P<0.01)。而不良反应轻微,其发生率与对照组比较差异无统计学意义(P>0.05)。结论:加巴喷丁能有效降低偏头痛的发作次数、疼痛程度及疼痛持续时间,而不良反应轻微,安生性较高。AIM： To evaluate the efficacy and safety of gabapentin in the treatment of migraine. METHODS： A randomized, double-blind, placebocontrolled study was taken. 104 patients（aged 18 to 60 year） with migraine were randomly assigned to receive placebo（ control group, 49 patients） or gabapentin （ experimental group, 55 patients）for 4 weeks. The efficacy, side effects, TCD and EEG were assessed at the beginning of trials, and 4th, 8th weeks. RESULTS： Comparing with the placebo group, the frequency, duration and intensity of migraine were markedly decreased in gabapentin group, there was significant difference between groups（P 〈 0.01）. The side effects did not differ between groups（ P 〉 0.05）. CONCLUSION： Gabapentin is an effective and safe agent from migraine.

关 键 词：加巴喷丁 偏头痛 随机 双盲对照 

分 类 号：R969[医药卫生—药理学] R747.2[医药卫生—药学]